18F-FDG PET/CT IN THE DIAGNOSTICS OF ENDOMETRIAL CANCER

18F-FDG PET/CT IN THE DIAGNOSTICS OF ENDOMETRIAL CANCER

Aretinskiy A.V. 1,2, Ternovoy S.K. 1,3

Purpose. This article is dedicated to analysis of use PET-CT with 18F-FDG for the last 10 years.Determining the presence of metastasis in regional lymph nodes and distant sites in endome-trial cancer is an important diagnostic step aimed at the choice of treatment tactics and im-provement of surgical treatment results. If the process is beyond the uterus itself, it signifi-cantly worsens the prognosis of survival. In addition, in these cases, it is necessary to change the treatment and surgical tactics. Determination of stage 1 and 2 of the process gives an optimistic prognosis for the survival of patients. Currently, ultrasound, magnetic resonance imaging and, to a much lesser extent, computed tomography are used to assess the preva-lence of the process. The diagnostic value of these methods according to some authors does not exceed 66-73%. In this regard, it is justified to work on finding more reliable methods that will more accurately determine the presence of metastatic disease in, both regional lymph nodes and distant organs. One of such promising methods is the use of positron emis-sion tomography combined with computed tomography (PET/CT), using as radiotracer 18 - fluorodeoxyglucose. This article is a review of the scientific literature on this problem over the past 10 years and is devoted to the evaluation of the diagnostic accuracy of PET/CT with 18F-FDG.
1- I.M. Sechenov First Moscow State Medical University (Sechenov Uni-versity). Moscow, Russia. 2- The federal network of Nuclear Medicine centers “PET-Technology”, Yekaterinburg, Russia. 3- Russian State Cardiology Research Cen-ter, Moscow, Russia.



 

Keywords: endometrial cancer, staging, 18F-fluoro-2-deoxy-D-glucose positron emission tomogra-phy/computed tomography, lymph node, magnetic resonance imaging (MRI), metabolic tumor volume, computed tomography (CT), recurrent cancer.

 

Corresponding author: Aretinskiy A.V., Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

 

For citation: Aretinskiy A.V., Ternovoy S.K. 18F-FDG PET/CT in the diagnostics of endome-trial cancer. REJR 2018; 8 (3):20-29. DOI:10.21569/2222-7415-2018-8-3-20-29.

Received: 09.06.18 Accepted: 16.07.18